LUNGLIFE AI, INC. Financials LungLife AI, Inc. Deutsche Boerse AG
Equities
9H4
USU5500L1045
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.172 EUR | 0.00% |
|
-6.52% | -76.44% |
| 04-05 | Transcript : LungLife AI, Inc., 2023 Earnings Call, Apr 05, 2024 | |
| 04-04 | LungLife reports narrowed losses in year of "considerable achievement" | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 64.81 | 26.2 | 14.92 | 6.199 | - | - |
| Enterprise Value (EV) 2 | 50.99 | 18.79 | 14.92 | 5.599 | 5.699 | 4.899 |
| P/E ratio | -5.29 x | -3.42 x | - | -1.51 x | 50.5 x | 7.48 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 331 x | 1,092 x | 324 x | 62 x | 12.4 x | 5.17 x |
| EV / Revenue | 261 x | 783 x | 324 x | 56 x | 11.4 x | 4.08 x |
| EV / EBITDA | -9.46 x | -2.75 x | -2.88 x | -1.56 x | -2.28 x | -2.58 x |
| EV / FCF | -5.43 x | -3.17 x | - | -1.56 x | - | 5.44 x |
| FCF Yield | -18.4% | -31.6% | - | -64.3% | - | 18.4% |
| Price to Book | 3.12 x | 2.05 x | - | 1.04 x | 0.99 x | 0.85 x |
| Nbr of stocks (in thousands) | 25,481 | 25,486 | 25,486 | 30,659 | - | - |
| Reference price 3 | 1.880 | 0.8500 | 0.4600 | 0.1600 | 0.1600 | 0.1600 |
| Announcement Date | 22-03-28 | 23-02-20 | 24-04-04 | - | - | - |
1GBP in Million2USD in Million3GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.1956 | 0.024 | 0.046 | 0.1 | 0.5 | 1.2 |
| EBITDA 1 | - | -5.39 | -6.84 | -5.19 | -3.6 | -2.5 | -1.9 |
| EBIT 1 | - | -5.714 | -6.555 | - | -3.8 | -2.7 | -2.1 |
| Operating Margin | - | -2,921.7% | -27,312.5% | - | -3,800% | -540% | -175% |
| Earnings before Tax (EBT) 1 | - | -7.428 | -7.602 | - | -3.9 | 0.1 | 0.8 |
| Net income 1 | -4.839 | -7.444 | -7.606 | - | -3.9 | 0.1 | 0.8 |
| Net margin | - | -3,806.41% | -31,691.67% | - | -3,900% | 20% | 66.67% |
| EPS 2 | -0.0412 | -0.3556 | -0.2484 | - | -0.1061 | 0.003170 | 0.0214 |
| Free Cash Flow 1 | - | -9.386 | -5.93 | - | -3.6 | - | 0.9 |
| FCF margin | - | -4,799.43% | -24,708.33% | - | -3,600% | - | 75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 112.5% |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-07-13 | 22-03-28 | 23-02-20 | 24-04-04 | - | - | - |
1USD in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 13.8 | 7.41 | - | 0.6 | 0.5 | 1.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -9.39 | -5.93 | - | -3.6 | - | 0.9 |
| ROE (net income / shareholders' equity) | - | -31.5% | -45.7% | -51.4% | -66% | 1.7% | 11.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.6000 | 0.4100 | - | 0.1500 | 0.1600 | 0.1900 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 1.85 | 0.09 | - | 0.1 | 0.1 | 0.1 |
| Capex / Sales | - | 944.61% | 354.17% | - | 100% | 20% | 8.33% |
| Announcement Date | 21-07-13 | 22-03-28 | 23-02-20 | 24-04-04 | - | - | - |
1USD in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.16
GBP
Average target price
2.2
GBP
Spread / Average Target
+1,275.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.89% | 7.8B | |
| +6.77% | 3.53B | |
| -1.35% | 2.24B | |
| -27.06% | 1.84B | |
| -21.23% | 1.66B | |
| +9.31% | 951M | |
| +29.42% | 811M | |
| -12.66% | 670M | |
| -26.12% | 533M |
- Stock Market
- Equities
- LLAI Stock
- 9H4 Stock
- Financials LungLife AI, Inc.
